Diagnostics will use Kinaxo
Biotechnologies’ phosphoproteomics technology, PhosphoScout
®, to find biomarkers
related to antibody-based therapeutics currently under development at Roche. The technology has been developed as a quantitative phosphoproteomic service, which the company says allows the dissection of cellular signal transduction pathways and their response to drug treatment. The platform is based on mass spectrometry methods, enabling the analysis of 15,000 phosphorylation sites in a single experiment.
The agreement follows just a week after Kinaxo announced a deal with Bayer Vital, under which PhosphoScout® will be used to identify novel biomarkers associated with drug response in a clinical trial evaluating Nexavar® in acute myeloid leukaemia patients.